Ming-Wei Chen and Fangheng Zhou, the scientists behind RephImmune, join hosts Lynnsey and Matthew to discuss how their biotech startup is developing a next-generation cell therapy platform designed to overcome the limitations of CAR-T.  With a focus on ovarian cancer, RephImmune’s RACE-T technology targets solid tumors by re-engineering immune cells to better locate, penetrate, and survive in the harsh tumor environment. Ming-Wei and Fangheng share their personal motivations, the science behind their approach, and how programs like SCbio DRIVE are helping them move closer to clinical trials. Tune in now!

Ver todos los episodios